Print this page

A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.

To collect long-term follow-up data on delayed adverse events after administration of cilta-cel, and to characterize and understand the long-term safety profile of cilta-cel.

Protocol Number: 012204
Phase: N/A
Applicable Disease Sites: Multiple Myeloma
Scope: National
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
    • Principal Investigator
      • Matthew Matasar
Inclusion & Exclusion Criteria ►

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.